Clinical trials indicate continuous glucose monitor (CGM) use in type 2 diabetes (T2D) can be beneficial across medication regimens and outpatient settings. CGM use in care for T2D is increasing rapidly, but little is known about predictors of CGM use in T2D. Adults (age 18-75) with T2D receiving primary care at an academic medical center enrolled in a RCT evaluating a self-management support intervention. The intervention did not address CGM use. At enrollment, patients completed an A1c test, self-reported demographic, clinical characteristics and individual (diabetes distress, diabetes self-efficacy, health literacy) , social (family/friend involvement, shared illness perception) , and behavioral (self-care behaviors) factors. The 15-month assessment queried CGM use in prior 12 months (current use/used and quit vs. no use) . We explored potential correlates of CGM use with unadjusted non-parametric tests of difference. Patients (N=109) completed 15-month assessments from July 2021 to March 2022. Mean age was 58±10 years; 57% female; 54% non-Hispanic white, 31% non-Hispanic black, 7% Hispanic; mean baseline A1c was 8.8%±1.8%. One-third (n=36) used CGM during the prior 15 months (including n=3 who quit) . CGM users were younger (median [IQR]: age 55 [47, 62] vs. 60 [53, 68], p=.031) , had higher baseline A1c (9.1% [8.1, 10.4] vs. 8.3% [7.5, 9.5], p=.048) and more were using insulin (69% vs. 36%, p=.002) as compared to non-users. CGM users also had higher baseline diabetes distress (45 [25, 55] vs. 30 [15, 50], p=.09) . CGM use was not related to gender, diabetes duration, race, ethnicity, health literacy, diabetes self-efficacy, family/friend involvement, perceiving diabetes as a shared illness, nor self-care behaviors. In a prospective study of adults with T2D from primary care clinics, younger age, insulin use, higher A1c and higher diabetes distress were associated with starting CGM. Two-thirds of CGM users were taking insulin. We did not find gender, race, ethnicity nor health literacy disparities in CGM use in our diverse sample.
L. S. Mayberry: Consultant; Abbott Diabetes, Cecelia Health. M. K. Roddy: None. S. S. Jaser: None. T. A. Elasy: None.
National Institutes of Health (R01DK119282)